Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for the info
Aleafia Health gains market share in adult use cannabis market, provides strong sales outlook
07:47 AM | Aleafia Health Inc. (ALEAF) | By: Khyathi Dalal, SA News Editor
Aleafia Health (OTCQX:ALEAF) indicated that it continues to expand market share by focusing on the highest revenue generating dried flower, pre-roll, and vape product categories.
It also changed business strategy to become a branded cannabis products provider, with branded cannabis representing 80% of total net revenue in 2021 compared to 33% in 2020.
In February, Aleafia Health achieved record 2.06% adult use market share in four major markets, advancing 33% from 1.54% in November 2021; market share in flower rose to 1.86% from 1.47%, pre-rolls rose to 2.62% from 2.09%, vapes rose to 2.18% from 0.92%, and oil rose to 4.01% from 2.68%.
Market share growth were hampered by temporary capacity limitations at the company's Grimsby greenhouse facility.
Besides receiving a $1M purchase order from Ontario for adult use products, it has secured purchase orders in 2022 YTD from Australia and Europe that exceed 2021 second half sales to international markets.
The company is targeting break-even adj. EBITDA profitability in 2H22.
Shares trading 5% down premarket.
So in your best guess, what do you foresee?
Aleafia Health Provides Further Update on its Convertible Debt
• Holders representing approximately 62% of total Debentures extend Forbearance Period until March 28, 2022 to allow negotiations to continue
TORONTO – March 16, 2022 – Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is providing a corporate update regarding its outstanding listed unsecured convertible debentures (TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022 (the “Convertible Debt”).
Further to the Company’s announcements on February 1, 2022 and March 1, 2022, the Forbearance Agreement, entered into between the Company and holders of Convertible Debt representing approximately 62% of the aggregate principal amount of debentures outstanding, has been extended until March 28, 2022. The Agreement automatically renews for 14-day periods thereafter unless advance notice to the contrary is provided.
The parties continue to work expeditiously and in good faith to negotiate a potential transaction to amend the terms associated with the Convertible Debt. While there can be no assurances regarding any outcome, the Company believes progress is being made towards a solution that is beneficial to its stakeholders.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health, a vertically integrated and federally licensed Canadian cannabis company, owns three licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history, and operates a strategically located distribution centre, all in the province of Ontario. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the adult-use and medical markets and is pursuing opportunities in select international jurisdictions. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
I really hope they get their act together. lol :)
Over the next 2 years, this company will either succeed, go out of business or be sold?
Unifor president Jerry Dias goes on medical leave to deal with health issues
Unifor president takes leave
The Canadian Press - Feb 16, 2022 / 3:52 pm | Story: 360327
The head of Canada's largest private-sector union has taken a leave of absence to deal with some health issues.
Unifor president Jerry Dias tweeted that his social media account will be quiet for a while.
Dias says he's confident that the Unifor leadership team and staff "will continue the important work of the union in my absence."
A note to local union presidents says Dias started a medical leave on Feb. 6.
The outspoken union leader was first elected national president in August 2013 at its founding convention and re-elected in 2016 and 2019.
National secretary-treasurer Lana Payne says she will work with the union's elected leadership team in Quebec, Ontario, the West and Atlantic Canada "to ensure the important work of our union carries on, in accordance with Unifor’s constitution."
Excellent info. Thank you for posting. I like the plan and hope the growth is solid. I still think the UNIFOR deal is a huge advantage. The youtuber I follow is a medical patient of theirs and she seems to get good results with their products. She was impressed with the effect of their live rosin even tho she is not using it recreationally.
Earnings Call Transcript: Aleafia Health, Inc. (ALEAF) CEO Tricia Symmes on Q4 2021 Results - Earnings Call Transcript
Feb. 15, 2022 2:14 PM ETAleafia Health Inc. (ALEAF)
https://seekingalpha.com/article/4487180-aleafia-health-inc-aleaf-ceo-tricia-symmes-on-q4-2021-results-earnings-call-transcript?mailingid=26720407&messageid=2800&serial=26720407.322&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=26720407.322
Aleafia Health, Inc. (OTCQX:ALEAF) Q4 2021 Earnings Conference Call February 15, 2021 9:30 AM ET
Company Participants
Tricia Symmes - CEO
Matt Sale - CFO
Conference Call Participants
Rahul Sarugaser - Raymond James
Operator
Good day, ladies and gentlemen and welcome to the Aleafia Health 2021 Fourth Quarter and Twelve Months Results Conference Call. This morning Aleafia Health filed on SEDAR its financial statements and associated Management Discussion &Analysis for the 3 and 12 months ended December 31, 2021.
All comments to be made on this call today should be taken with reference to and are qualified in their entirety by those documents. Today's call includes estimates and other forward-looking information from which our actual results could differ. Please review the cautionary language in today's press release regarding various factors, assumptions and risks that could cause our actual results to differ.
Furthermore, during this call, we will refer to certain non-IFRS financial measures including branded cannabis net revenue, adjusted gross margin and adjusted EBITDA. These measures do not have any standardized meaning under IFRS, and our approach to calculating these measures may differ from that of other issuers and so these measures may not be directly comparable. Please see this quarter's MD&A for more information about these measures.
I would now pass the call over to our Aleafia Health’s CEO, Tricia Symmes.
Tricia Symmes
Thank you, Howard, and welcome fellow shareholders. I am very excited about Aleafia’s future and an exciting year ahead of us. The prospects for our company are the best they have ever been and we look forward to continuing to show shareholders and investors what great things we can do in this industry.
Our mission is very direct, to improve peoples’ lives and that is what will see us realize our personal and business ambitions. Embracing this mission is now more important than ever. First off, I would like to thank Geoff Benic, our former CEO for the last 3.5 years for his leadership, passion, and mentorship to Aleafia Health. He put together a phenomenal team, got Aleafia off the ground and where we are today and we wish him well in his next challenge.
Now, let’s talk about the company as it is today. The core strategic objectives that will drive Aleafia Health to sustained profitability, reflect a pivot to focus on branded cannabis revenue. In 2021, we transformed our business evolving from a wholesale producer to a branded cannabis company and that is a major change.
Today, you’ll hear the words sticky and hyper growth. Two concepts that are driving us forward. Sticky of course means that sales will occur over and over as customers will be using our products again and again. It occurs in the medical cannabis segment where the revenue is recurring at attractive gross profit margins. And hyper growth characterizes our trajectory in both the adult-use sales channel and the opportunity we see in select international markets.
Now let’s talk about Aleafia’s transformation and what has this meant to our Q4 and 12 months results. Our revenue is driven by three strategic pillars, an exciting CPG branded adult-use portfolio, generating $24 million runrate net revenue. Leadership in medical cannabis with its $10 million runrate net revenue and burgeoning international sales where we are well positioned in three countries, Germany, the UK and Australia and have developed partnerships with key established European supply distributors.
We consider international sales to be an important opportunity and have already delivered products overseas. More to come on that. Another highlight is that we are targeting the second half of 2022 to achieve breakeven adjusted EBITDA profitability. To do this, we are improving adult-use margins through portfolio optimization and we are reallocating the company’s headcount strategically to optimize talent and maximize revenue velocity.
I can tell you today that we are poised to achieve a top 10 market share position in 2022, driven by leadership in the broad ranging adult-use value cannabis category. Our very appealing Divvy value brand is consistently among the top search brands at the Ontario cannabis store. Our five cannabis brands span the spectrum from premium and craft flower to the value category where we enjoy significant leadership.
Since Q4 2020, 37 new SKUs have been launched as we are aggressively pursuing and gaining market share in the three largest categories, dried flower, pre-roll and vape. We are pleased to report that Aleafia delivered a top three change in market share rankings out of 40 Canadian licensed producers from Q1 2021 when we launched our Sunday Market House of Brands to Q4 2021.
Here is what the results tell us. In 2021, the total net cannabis net revenue of $36.1 million represented a highly diversified sales mix with our two hyper growth segments in adult-use and medical cannabis achieving 80% of net revenue, a complete turnaround from 2020 where bulk wholesale products represented 67% of net revenue. This is a complete change.
We are moving away from lower margin bulk wholesale sales where the relationship with the consumer is distant. Our focus now is to understand and deliver what the consumer demands.
To look at it another way, for the 12 months period ending December 31, 2021, branded cannabis net revenue advanced 96% to $28.7 million from $14.6 million in 2020. For Q4 2021 it increased 60% to $8.3 million from $5.2 million in Q4 2020. We are in the top three of Canadian LPs in market share rank increase to number 15 in Q4 2021, up from number 30 in Q1 2021. There was also a 37% rise in Q4 2021 retail sales pull through relative to Q3 2021.
Aleafia is now a branded products company and we are very proud of our Sunday Market House of Brands. It has achieved 396% growth year-over-year and it is anchored around Divvy, the everyday brand focused on quality, high margin and high velocity categories including, dried flower, pre-roll, vapes and select cannabis derivative products.
We delivered top 10 Q4 2021 retail sales increase relative to Q3 with a 37% sales growth. The company’s adult-use market share increased from 0.3 in Q1 2021 to 2.0 in Q4 2021. Adult-use net revenue increased a very impressive 396% to $16 million, compared to $3.2 million in 2020 and increased 326% to $6 million in Q4 2021, compared to $1.4 million in Q4 2020.
So this growth was led by expansion of our flower and pre-roll retail sales, which each grew by 1000% during the last quarters. Our Divvy value brand, a top search brand on OCS.ca reached the tenth percentile in Ontario for its vapes and its oils, our one of the top SKUs in the province.
Our market share is on a dramatic upward trend rising 27% Q4 versus Q3 2021 and achieving 15 positions from 30 at the end of Q1 2021 when the Sunday Market House of Brands was launched to 15 at Q4 2021. In the second half of 2021, there was approximately a three times increase in gross adult-use sales over the first half of 2021.
This momentum has continued into 2022 as you can see our market share rank continues to rise. Over this period, the company delivered strong retail pull-through at each of the three major categories with flower retail sales climbing approximately 1400%, pre-roll increasing approximately 1000% and vape retail sales increasing approximately 200%.
Aleafia is a significant player in the medical cannabis market through our flagship emblem brands and there too revenue is climbing to its sticky and recurring revenue base with strong gross margins. Medical cannabis net revenue increased 33% to $10.6 million in 2021, compared to $8.0 million in 2020, driven by strong script growth and new strategic clinic and benefit provider partnerships that see the benefit in joining the Aleafia medical ecosystem.
Script count increased 17% year-over-year, while the market declined at minus 23%. We had double-digit growth in medical cannabis sales despite the overall market decline. Third-party clinics now represent just about 55% of gross medical revenue and four new unionized employers were added in 2021. Key wins include a 22% increase in Unifor patients in Q4 over Q3, a 67% increase in prescriptions from veteran patients in Q4 2021 over Q3 2021, and a 2000% increase in Quebec scripts in Q4 2021 over Q3 2021.
The medical channel represents a highly scalable sticky recurring revenue base. Through Unifor and our new strategic partnerships, we are poised to accelerate new patient uptake and continue to pursue those patients who reimbursed for their medical cannabis. We are seeing strong fundamentals relative to our competitors with year-over-year script count up 17% from 32,191 in 2020 to 37,779 in 2021and an active patient base, which grew 13% from 17,400 in 2020 to 19,700 in 2021.
One of the important drivers of our competitive advantage is in producing large format dried flower SKUs in Port Perry, one of the only successful outdoor cultivation facilities in Canada. As one of the first operational, large-scale legal outdoor growth in Canadian cannabis history, it launched in 2019 and was an industry disruptor that enabled Aleafia’s strategic pivot as we began to produce large-scale harvest of THC dried flower.
Dry flower and pre-rolls represent more than half of the total adult-use market and we are a high quality and low cost producer of dried flower. A record-breaking outdoor harvest in 2021 puts us in a strong position to supply our burgeoning adult-use sales channel. Thanks to the expertise of the team there, we produced high potency flowers that averaged 22% THC, and reached up to 27% THC, the kind of level consumers are looking for.
We are seeing the market of both such as an addition to potency consumers are paying increasingly more attention to terpenes which ran from 2.7 to 5.7 in 2021, compared to a maximum 3.3 in 2020. The harvest this year is exponentially higher quality than 2020. In high potency flower we cultivated approximately 500 kilos in 2020, versus 11,650 kilos in 2021, all of which is the highest grade flower already being sold at retail under the Divvy brand.
I will now turn the presentation over to Matt Sale, our CFO and he will tell you more about some of Aleafia’s important metrics. Matt?
Matt Sale
Thank you, Tricia. Good morning. It’s great to speak with you all today. In this quarter and the 12 month period, there are many deciding moments that point toward the kind of company Aleafia is rapidly becoming. Our product mix has shifted almost completely to branded cannabis adult-use and medical products from lower margin bulk wholesale products.
Net branded cannabis revenue increased 96% over 2020 to $28.7 million and now represents 80% of our total net revenue. This is a complete turnaround from 2020 where bulk wholesale products represented 57% of total net revenue. This was driven in part by the redirection of high potency flower from our outdoor harvest in Q4 to the adult-use sales channel where it will supply higher revenue per gram products in the first half of 2022.
We have diversified our sales mix with higher quality, direct-to-the consumer, adult-use and medical sales which delivered stronger growth and net realizable margin. They are more stable, provide greater visibility into future revenue and pave the way for sustainable long-term top-line growth. This change leads the emergence of Aleafia as a leading consumer package goods or CPG company with multiple brands.
We call this our House Of Brands and believe they will win consumer loyalty enabling a sticky, quality revenue stream for Aleafia as evidenced by the success of Divvy. With branded cannabis net revenue now representing 80% of our total, we believe this is a significantly more diversified revenue base, while delivering higher growth and net realizable margin.
Now let me unpack some of the key growth drivers in our adult-use business. We generated 1.7 million of net cannabis revenue in Q1 2021, $3.2 million in Q2 2021 and $5 million in Q3, and $8.3 million in the most recently completed Q4 2021 period representing a healthy 19% quarter-over-quarter increase and a 1237% compounded annual growth rate since Q3 2020.
While the Q3 and Q4 increases have been strong, the net cannabis revenue could actually have been meaningfully higher as consumer demand evidenced by purchase orders from the provincial supply boards exceeded our ability to fulfill them as we experienced operational inefficiencies in our Grimsby Ontario indoor growth facility.
Adult-use cannabis, including flower, pre-rolls and vapes is our single largest sales channel with a highest growth rate and is exactly where we want to be. In the second half of 2021 there was an approximate three times increase in the adult-use retail sales pull-through of our products over the first half of 2021 based on Highflyer data.
Catalysts for this growth included accelerated retail penetration, our portfolio optimization, and expanding our cultivation capacity with a continued focus on high value flower at an attractive price point. Our outdoor harvest positions us well to continue ramping adult-use net revenue as this high potency flower can be redirected into the large format pre-rolled category.
We are already seeing robust purchase order activity in the first six weeks of this quarter positioning us well to continue our quarter-over-quarter growth trajectory. As you may recall, Aleafia began its journey in cannabis in the medical sales channels with the acquisition of Emblem and in 2021, we built on that success with the expansion of our medical ecosystem.
This channel is an important one for Aleafia. Our medical business is growing and we are optimistic about its future. Our net revenue over the last eight quarters has increased from $1.4 million in Q1 2020 to $2.2 million in the most recently completed Q4 2021 period representing a CAGR of 30%. We are encouraged to continue this quarter and at numerous favorable tailwinds and initiatives to drive this, we are focused on growing our active patient base. Under our exclusive Unifor partnership, we onboarded four unionized employers in the second half of 2021 and see lots of runway.
With each new employer onboarded, we refine our process to expedite the onboarding our new future new employers. Additionally, we are targeting expanding clinic partnerships by 20% with numerous new potential clinic partnerships in our pipeline with attractive underlying active patient bases. We are focused on serving high value patients that have higher average ordering values or AOVs and order frequency.
As an example, we see certain veteran patients that exhibit AOVs that are 2.7 times that of our non-veteran patient base and order twice as frequently. We are relentlessly focused on better serving our patients and are undertaking a complete restructuring to integrate our physical clinics, our virtual clinic, and third-party clinic platforms and believe this will drive operational efficiencies, reduce our SG&A profile and unlock future revenue growth.
Our medical ecosystem is positioned to continue leading the industry with research education for clinic partners and our active patient base to ensure they all continue engaging with our ecosystem. Reducing adjusted SG&A expenses are a key driver to profitability for us. Adjusted SG&A declined 35% from $11.2 million in Q4 2020 to $7.1 million in the most recently completed Q4 2021 period.
We implemented several initiatives throughout 2021 to reduce our cost profile and make our infrastructure scalable to sustain significantly higher revenue volumes. We implemented an internal direct sales force to sell into both the adult-use and medical channels. We put in place an operational management team at each of our three production facilities who are capable and prepared of managing significantly higher ordering throughput.
We developed a suite of corporate shared services including information technology, finance, human resources and legal, which are now leveraged across all our sales channels. Further, we saw a significant non-recurring cost in the first half of 2021 related to our House of Brands build out which are now largely complete.
The company reviewed its inventory and fixed assets and identified certain slow moving assets primarily related to the bulk wholesale sales channel. As a result of the company’s focus on branded consumer products, the company recorded a $19.6 million inventory provision. Additionally, the company recorded a $28.8 million impairment of property plants and equipment due to changes in marketing conditions for these assets.
Although we have made great progress in 2021 reducing our quarterly adjusted [Indiscernible] by 35% over the last four quarters, while branded net revenue grew 60% over that same time period, we have further initiatives actively underway to reduce costs and enhance profitability. We have a renewed focus on cost discipline to accelerate the pathway to adjusted EBITDA breakeven profitability. We are focused on enhancing gross profit margins.
Total adjusted gross profit margin before fair value adjustments and inventory provision was 27% in Q4 2021, compared to 50% in Q4 2020, primarily due to the company’s focus on branded cannabis products that deliver higher overall net margin per gram. We are undergoing a SKU optimization to align our portfolio and best selling product formats to optimize our margin profile.
Moreover, we believe the market can bear moderate, strategic price increases while still achieving an attractive value proposition for our products. We are optimizing our operating expense profile to further extract cost and drive towards profitability. In that regard, we’ve reviewed our sales channels to embrace those that deliver the highest net realizable margin per gram of flower sold and we methodically reviewed Aleafia’s cost structure to optimize our talent and resources towards those channels.
The company completed a strategic restructuring plan in the second half of 2021 which saw significant headcount reductions. In Q4 alone, the headcount reduction continuing into early January 2022 represents $1.9 million in annualized savings. We are integrating our physical, virtual and third-party clinic medical channels, which is expected to further optimize our cost profile and facilitate new patient onboarding and servicing on an ongoing basis.
In 2021, we delivered $36.1 million in total net revenue and currently our runrate to net revenue is approximately $41.9 million. This is based on approximately $24 million in adult-use, $10 million in medical, and international and $8 million in bulk wholesale net revenue. We have a multipronged growth strategy to scale, distributing $53 million and $63 million in net revenue in fiscal year 2023.
The core pillars to achieve this are, attaining a top 10 market share position in the overall Canadian adult-use market by focusing on quality, high margin, and high velocity sales categories; expanding our leadership position in medical by onboarding additional third-party clinics and accelerating market uptake under our exclusive Unifor partnership; building on existing partnerships to unlock the key European market and continue driving expanded international sales.
To help finance these ambitious growth targets, the company completed two financings in the second half of 2021 including a $10 million senior secured term credit facility in August, and a new $19 million credit facility in December. The new credit facility consists of a $12 million term loan and a revolving receivables facility up to $7 million.
The revolving receivables facility remains undrawn providing the company with liquidity to fund working capital investments required to continue rapidly scaling our adult-use sales. The company is also actively engaging with holders of our listed unsecured convertible debentures maturing on June of 202 with a view to effecting changes in key terms that are equitable to both the holders and the company and provide a sustainable foundation for the company’s continued growth.
We believe these fiscal year 2023 targets for net revenue, adjusted gross profit margin, adjusted SG&A, and adjusted EBITDA are achievable based on the strategies we have outlined here today.
Tricia over to you.
Tricia Symmes
Thank you, Matt. As demonstrated, we have launched a multipronged growth strategy across three high value pillars to achieve these estimated growth projections. The pillars are, adult-use, in which our goal is to attain top 10 market share in the overall Canadian adult-use market; medical, where we will onboard additional third-party clinics and accelerate market uptake under the exclusive Unifor partnership; international, where our goal is to build on existing partnerships to unlock the key European market.
I became CEO on February 7th of this year. Previously, I was the company’s Chief Commercial Officer. My background is in building and rebuilding companies and taking them to the next level of growth and profitability. A big part of our mission is engaging with the consumer and to accomplish that, we’ve attracted a very lean top executive sales and marketing team with an internal sales force that truly understands the CPG marketplace and what consumers want.
Our team is focused on the need to drive value, to secure loyal customers, and drive and maintain market share. Aleafia’s success will be based on understanding the consumer and providing a value proposition that others have not capitalized on and this is why we are achieving hyper growth.
In 2022, we intend to be leaders in our three pillars, adults, medical and international. We are very optimistic and we would like you to share in this optimism. For Aleafia Health the best is yet to come.
Thank you for being here today and listening to this presentation. We will now take questions.
Question-And-Answer Session
Operator
[Operator Instructions] Our first question or comment comes from the line of Rahul Sarugaser from Raymond James. Your line is open.
Rahul Sarugaser
Morning, Tricia and Matt. Thanks so much for taking my questions today. So, congratulations on the large percentage growth that you’ve seen, particularly in the adult-use throughout in the medical channel. So, I guess, my first question is, while those splendid increases are, I would say, on a dollar basis, it’s not, it took to the middle of the pack. And given that market share really is determinant of success in the Canadian market and that Aleafia sitting at around, maybe plus or minus 1.5% to the adult-use and become relevant we need to be at least 1.3% to potentially 5%, how do you plan on – so how does your roadmap drive you towards that sort of relevant market share?
Tricia Symmes
Well, thank you, very much for your question. I think your points are very valid. I would provide a few answers to help clarify. So first of all on the adult-use of the business, I think what’s important to know is that we only entered into the adult-use of the business in the second half of 202. And really this is going to be the first full year that we will see sustainable runrates with the Divvy health – with the Sunday Market House of brands and with Divvy. Our projection this year will help take us north of that 3% market share that you shared on and really what that’s going to be driven by is, obviously the superior and strong brands that we are containing in the value category, but also with us going into larger formats that we discussed in terms of the flower, we know the product and other segments such as these in which those products were not previously launched in the first part of this year.
We’ll also start to see a more of a sustained runrate of these products as we did have some supply challenges in the last part of 2021 where we had actually greater demand for our products than we were able to pull through. We are now starting to see significant improvements in our greenhouse and we are also seeing significant improvements in operational efficiency.
And we really believe that we’ve built a brand that consumers want. It’s really focused around, obviously, high quality product that obviously offering as a value that is sustainable for consumers and strain that we maintaining that sticky revenue. So the adult portion of our business will continue to be a very strong growth driver as we start to realize those consistent runrates and increase exponential growth quarter-over-quarter.
We are also looking at strategic price adjustments within our portfolio. As you know, it’s very important for us to establish the brand first and create a loyal consumer following and as we start to move into some of those higher categories that obviously can generate more improved margins for us and increase the brand strategically just will have a very important effect on the overall adult-use portfolio.
I think the second most important part of our continued growth to generate, obviously, higher market share value the company will be in the medical side of the business. We have an exclusive partnership with Unifor where, as you pointed out there are some good growth improvements in Q3 and Q4. But unfortunately, due to COVID and the challenges that many companies have experienced there, it was very difficult to be present in front of potential patients to be able to onboard them as quickly as possible. We have actually seen excellent growth in new players onboarding with us that will be ratifying those agreements and fee insurance coverage. And we’ve also just acquired the retiree base which represents a significant increase in new medical patients that will have access to over $2,500 per year in reimbursed medical benefits of cannabis. So that will continue to be a very important pivotal part of our growth as the medical part of the business is sticky and recurring revenue and obviously at higher margins.
And then the last portion which is obviously one that we are extremely excited about is the international side of the business. Again it’s a key differentiator for us to help move and improve our market share overall in the Canadian market is that these are at much higher margins and a higher price point. We’ve already established excellent partnerships in the end of 2020. We have leveraged our first shipments in two European markets and we already have a strong base of PO’s export comments that will capitalize on as we move into 2022.
So, it’s really the three pillars that will help to take us to that next level and get us into the top 10 LP status that we just discussed on this call.
Rahul Sarugaser
Great. Thanks for the additional color. So, to drill down then on the medical side specifically and in terms of the Unifor contracts, which is because we cover the healthcare space more broadly, certainly seeing the difficult for sales folks irrespective of where the healthcare industry get into talk to, whether it’s doctors or patients? But now that that’s opening up hopefully, that certainly should benefit your sales team. So, how should we be thinking about that channel starting to provide material and durable revenues and what should we be thinking in terms of the timeline for that?
Tricia Symmes
Yes. Excellent, excellent question. So the medical cannabis pillar of our business, as you mentioned is a key strategic future growth driver. And it’s based kind of on a multi-pronged strategy. The first is, a strong and growing patient base. So we did recognized this in 2021 and we are one of the only medical companies to be able to continue to increase patient base and show growth versus an overall decline in the industry which is largely driven by a lot of consumers moving towards the adult segment. We believe that it’s important to continue to grow this side, it’s a sticky revenue base and it’s also one in which we have a lot of control with our own virtual clinic pipeline. That’s an important transition that we made this year outside of the brick and mortar to be able to seek patients virtually and make sure that access was easier for these patients that will continue to onboard new patients , which you know it’s one of the important points of this is onboarding patients that then continuing to be able to repeat their prescriptions. The other focus for us in the medical side which we are seeing tremendous growth in Q4 over Q4 was based on our third-party partnerships and we’ve taken a strategic look at how we can have exclusive partnership with Unifor over this 300,000 members that more importantly how we can onboard those potential patients at a more rapid level as we commented this COVID period. And that we’ve also looked specifically at other third-party benefit providers, partnerships in both the Quebec market and with veterans that are all a recurring revenue base that will help to strategically grow our medical platform and ensure that this becomes a critical pillar of ours.
I think the other thing that I would mention is, despite the challenges that many of us experienced during this COVID period, we were still able to onboard four new employers. And that only represents less than 5% of the total opportunity with that Unifor base as these agreements begin to become ratified as we have opportunities to be in front of these potential patients in person through education and onboarding and as we start to tap into the retiree group, which just received their reimbursement at the end of January this year. This will help to see substantial increase in growth in our medical platform and we really believe that this will be a catalyst for moving us into that higher insurance covered area for medical patients, which is really income for pharmaceuticals is the most important thing that you have a platform where patients can have reimbursement for their therapy and that is one that can be continuous recurrent and sticky. So this is part of our strategy on the medical side to help inflate and accelerate our growth.
Rahul Sarugaser
Great. Thank you for that and we’ll certainly look forward to seeing growth there. And if you – and just one last question just around margins, given that historically margins were quite dynamic given especially outdoor indoor growth, the mix between wholesale and close to different channels. So, how should we be thinking about margins so that in medium-term as they sort of settle out and as you start to focus on these three primary channels that you highlight?
Matt Sale
Thanks for the questions. I think directionally where Q4 was is a good starting point to think about our margin profile that I will say with the change in sales mix towards branded cannabis products away from wholesale. The biggest benefit we see is in margin per gram sold. So, it’s as a post is looking at eight percentage, wholesale directionally has had quite a bit of volatility over time with some quarters quite higher and in Q3 in particular it was quite a bit lower. Our adult-use portfolio and our medical portfolio, I think will each deliver margins in and around the kind of 30s to 40s with medical I think at the higher end of that and adult at the lower end of that. And depending on our sales mix, it will move around. The guidance we are putting out for fiscal 2023 is to achieve between 32.5 and 37.5.
Rahul Sarugaser
Thanks. That’s actually very helpful. I appreciate you lining those numbers. And thank for taking our questions. I will get back in the queue.
Tricia Symmes
Thank you.
Operator
Thank you. Our next question or comment comes from the line of [Indiscernible] from Research Capital. Your line is open.
Unidentified Analyst
Hey guys. Thank you for taking our questions. My first question was, I was wondering how we should think about the relationship with wholesale going forward?
Matt Sale
Yes. Thanks for the question. So, wholesale, it historically was a very important part of our revenue mix and 2020 represented two-thirds of total net revenue. As we have now launched our House of Brands and are focused on branded cannabis products we see it having a – overall a lower percentage of our total net revenue. I will say it is still a – it can be an important sales channel, particularly for spec or lower quality flower that we are able to maximize the net realizable margin on our entire harvest. But I think going forward, really our focus is you should expect to see a majority of our revenue based on branded cannabis products.
Unidentified Analyst
Okay. Awesome. Thank you. I was also wondering if there will be any seasonality impacts on revenue in Q1?
Matt Sale
Yes, from a seasonality perspective, I think our medical business is the – it has some ebbs and flows, particularly in the summer months, inability or less focus on getting prescriptions refilled. But generally is a sticky recurring type revenue base. So, each quarter is pretty consistent over the period saw that least volatility. Our adult-use business, I think we are having just – strong growth in Q4 growing over 19%. We see that same momentum continuing in Q1of this year and throughout fiscal 2023. I think in the first half of this year, we have the benefit of our outdoor harvest which only comes down once a year. So that will really benefit the first half momentum more so than the second half momentum. And then on international, and wholesale, I’ll say, wholesale is less – we were less able to predict seasonality. I think it’s much more opportunistic and – than the other three sales channels. That – hopefully, that’s helpful to you. Operator, next question?
Operator
Sir I am showing no additional questions in the queue at this time.
Tricia Symmes
Well, thank you very much for spending this morning with us and we look forward to continuing to update on our journey as we move through this next exciting period. Thank you very much.
Matt Sale
Thank you.
Operator
Ladies and gentlemen, thank you for participating in today’s conference. This concludes the program. You may now disconnect everyone.
I am sitting on a substantial position I wish I sold out at 90¢ ... Aleafia is bleeding money via EBITDA and debt. They were thrown a lifeline that required the change at the CEO level.
We're hanging by a thread.
This is actually very good considering Canopy’s net cannabis revenue was only $89 mil! These are still early days and I am glad I have a good position in this company. I wish I could buy more right now I do not like companies that aspire to be bought out. I want a company that is carving out a place for itself for the long run.
https://ih.advfn.com/stock-market/TSX/WEED/stock-news/87230137/canopy-growth-reports-third-quarter-fiscal-2022-fi
See RED and blue highlights to see how small Aleafia is--->>> Aleafia Health Reports Q4 2021 Financial Results with $11.5 Million Branded Cannabis Gross Revenue, representing a 103% Increase from 2020
• Transforming business towards a branded cannabis provider, with branded revenue representing 80% of total net revenue in 2021 compared to 33% in 2020
• 96% increase in branded cannabis net revenue to $28.7 million in 2021 from $14.6 million in 2020
• 396% increase in adult-use net revenue to $16.0 million in 2021 from $3.2 million in 2020
• 60% increase in branded cannabis net revenue to $8.3 million in Q4 2021 from $5.2 million in Q4 2020
• 33% increase in medical cannabis net revenue to $10.6 million in 2021 from $8.0 million in 2020
• Consolidating medical market share with 17% growth in scripts in 2021 relative to 23% overall market decline
• Average THC potency of 22% with up to 27% levels achieved in record-breaking outdoor harvest
• Projecting Adjusted EBITDA Profitability during the Second Half of 2022
TORONTO – February 14, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to report its financial results for the three and 12 months ended December 31, 2021. The Company’s 2021 unaudited, consolidated financial statements and management discussion and analysis for the fourth quarter and 12-month periods will be available in the Investors section of the Company’s website at aleafiahealth.com and will be filed on SEDAR and available at sedar.com.
“The core strategic objectives that will drive Aleafia Health to sustained profitability reflect a pivot to focus on branded cannabis revenue. Branded revenue is comprised of ‘sticky,’ recurring medical revenue at attractive gross margins and robust growth in adult-use cannabis revenue where Aleafia continues to aggressively take market share,” said Aleafia Health CEO Tricia Symmes. “We are focused on achieving Top 10 in total LP market share in 2022, driven by leadership in the value cannabis category. Aleafia’s five cannabis brands span the spectrum from premium and craft flower to the value category with Divvy, where we already enjoy significant leadership. The company’s market share rose from 30th in Q1 2021, when we launched our House of Brands, to 15th in Q4 2021, representing the third highest change in market share rankings out of 40 Canadian Licensed Producers (“LPs”).(1) Q4 retail sales increased 37% relative to Q3. Our Divvy value brand is consistently among the top searched brands at the Ontario Cannabis Store website.”
“In 2021, the total net revenue of $36.1 million represents a highly diversified sales mix. Driven by robust growth in adult-use and medical sales, these two sales channels represented 80% of total net revenue, a complete turnaround from 2020, where bulk-wholesale product represented 67% of total net revenue,” Symmes added. “This is just the beginning, and we are very excited about the future. A record-breaking outdoor harvest that produced average THC potency of 22% allows us to direct this flower into the adult-use market, delivering significantly higher net margin per gram than the bulk wholesale channel. With our highly competitive THC levels, the quality of the brand is the company’s competitive advantage in the value category, and by focusing on the top performing high margin products through portfolio optimization, we are poised to achieve breakeven adjusted EBITDA profitability in the second half of 2022.”
“Aleafia Health’s revenue is driven by three strong business lines: its CPG branded adult-use portfolio, where we aim to enjoy a Top 10 overall market share position, which currently generates $24 million annualized run-rate net revenue, with significant momentum in the first 6 weeks of 2022; leadership in medical cannabis with its highly recurring $10 million annualized run-rate net revenue, and a 17% increase year over year in script counts; and international sales, where we are well positioned in three countries, Germany, the UK and Australia, and have developed partnerships with key established European supply distributors.
Our Sunday Market House of Brands achieved 396% growth year over year and is anchored around our hugely successful everyday Divvy brand, we have moved strongly ahead into categories that consumers want and are providing the innovative products and a value proposition that they demand.”
OPERATIONAL HIGHLIGHTS
• Net revenue was $36.1 million for the 12 months ended December 31, 2021 (“2021”), compared to $44.5 million in the 12 months ending December 31, 2020 (“2020”). For the three months ended December 31, 2021 (“Q4 2021”), net revenue was $8.8 million, compared with $15.2 million in Q4 2020. The decline in net revenue was based on shifting from lower margin, higher volume bulk wholesale commodity cannabis revenue to higher margin, higher potency and innovative adult-use products, offering a unique value proposition. The Company’s branded cannabis revenue includes its “sticky” medical sales and market share consolidating branded adult-use cannabis products along with its burgeoning international sales.
• Branded cannabis net revenue increased 96% to $28.7 million in 2021 compared to $14.6 million in 2020, and increased 60% to $8.3 million in Q4 2021 compared to $5.2 million in Q4 2020, largely attributable to the launch of the Sunday Market House of Brands, which enjoyed 396% growth in 2021 compared to 2020, anchored around Divvy, the everyday brand focused on potency and an exceptional value proposition. Aleafia delivered the top 3 out of 40 Canadian LPs in market share rank increase from Q1 2021 (#30) to Q4 2021 (#15).(1)
• Adult-use net revenue increased 396% to $16.0 million in 2021 compared to $3.2 million in 2020, and increased 326% to $6.0 million in Q4 2021 compared to $1.4 million in Q4 2020. Sales velocity continues to accelerate driving market share capture with 37% retail sales pull through in Q4 2021 relative to Q3 2021.(2)
• Medical cannabis net revenue increased 33% to $10.6 million in 2021 compared to $8.0 million in 2020, driven by strong ordering patterns from its flagship Emblem cannabis brand. Script count increased 17% year over year, to 37,779 in 2021 compared to 32,191 in 2020. The patient base grew 13% to 19,700 in 2021 from 17,400 in 2020. In 2021, the Company onboarded four unionized employers through its exclusive partnership with Unifor, Canada’s largest private sector union, with more than 515,000 members and retirees across the country. The highly scalable new patient onboarding platform is well-positioned to accelerate patient uptake. The Company will continue pursuing its recurring revenue base in which patients receive reimbursement for medical cannabis.
• Bulk wholesale net revenue declined 75% to $7.4 million in 2021 compared to $29.9 million in 2020, which was offset in part by strong growth in branded cannabis revenue. This was driven by the Company’s redirection of its cultivation flower from the bulk wholesale sales channel towards its higher net revenue per gram branded cannabis products.
• The Q4 2021 outdoor harvest delivered over 11,600kg of high potency saleable flower with THC levels averaging 22%. The Company plans to primarily utilize this product in the first half of 2022 in its adult-use branded cannabis products.
• Total gross profit fair value adjustments and inventory provision was 31% in Q4 2021, compared to 59% in Q4 2020, primarily due to the Company’s pivot away from bulk-wholesale towards branded cannabis products that deliver higher overall net margin per gram.
KEY DEVELOPMENTS
In 2021, the Company transformed its business to become a branded cannabis provider. It has produced high potency flower at its Port Perry outdoor growth facility, allowing it to direct that product to higher margin, adult-use products. It has engaged?with the consumer and attracted a top executive sales and marketing team, with an internal sales force, that understands the CPG marketplace, what consumers want and is focused on the need to drive value to secure loyal customers and drive and maintain market share. Higher THC levels as well as the lower cost of input materials has allowed the Company to significantly increase its market share. Other developments include:
• Branded Cannabis Represented 80% of 2021 Total Net Revenue: The Company launched 37 new SKUs since Q4 2020 and built five cannabis brands spanning value to premium, craft. Divvy, an everyday consumer value brand, is consistently a top searched brand on OCS.ca. Twelve new product formats were launched in 2021 including: Craft Dried Flower, Milled Flower, 1g Distillate Vapes, Live Resin Vapes, Live Resin Diamond Sauce, Salted Caramel Pretzel Bites, Cluster Pucks, HotSauce, Omega CBD Soft Gels, Bath Bombs, Freshly Minted Roll-Ons and Topical Creams.
• Significant Increase in Adult-Use Market Share: The Company is aggressively capturing market share. It achieved a top 3 market share rank increase among 40 Canadian LPs in the Q1 2021 (#30) to Q4 2021 (#15) period, based on HiFyre data. Its 37% increase in retail sales pull through from Q3 2021 to Q4 2021 placed it among the top 10 Canadian LPs. The Company’s market share increased from 0.3% in Q1 2021 to 2.0% in Q4 2021. Over this period, the Company delivered strong retail sales pull through in each of the three major categories, with flower increasing approximately 1,400%, pre-roll increasing approximately 1,000% and vape increasing approximately 200%. The Company enjoys 94% penetration at the retail store level in Ontario and 84% in Alberta, and has supply agreements with Saskatchewan and British Columbia.
• Medical Ecosystem Expanded: The Company onboarded four unionized employers in 2021 through its exclusive Unifor partnership. These employers represent less than 5% of the Unifor member base and the Company continues to focus on additional onboardings. Despite restrictions on interacting directly with potential patients due to Covid-19, the Company experienced modest growth in both Unifor-based patients and sales from Q3 2021 to Q4 2021. The Company saw scripts increase 17% year over year, driven primarily by continued onboarding of third-party clinics which represented a largely reimbursed patient base comprising approximately 55% of total medical sales in Q4 2021. The Company launched tailored programs targeted at the Veteran medical demographic and entered the Quebec market.
• International: The Company successfully saw its products exported into three countries Germany, UK and Australia in 2021. The Company established partnerships with key European suppliers and wholesalers to facilitate a ramp-up in pull-through into the European market in 2022.
• Cultivation: The Company owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including in Port Perry the first large-scale, outdoor cultivation facility in Canadian history. Port Perry delivered over 11,500 kg of flower with average THC potency of 22% in 2021. THC levels ranged from a record-breaking 21-to 27% and the terpene profile was outstanding, ranging from 2.7% to 5.7%.
• Cost Rationalizations: The Company methodically reviewed its cost structure and optimized its talent and resources towards the sales channels which delivered the highest net realizable margin per gram of flower sold – its branded cannabis products. The Company initiated headcount reductions in Q4 2021, representing approximately 10% of the workforce and approximately $1.9 million in annualized savings. The Company has undergone a SKU optimization to align its portfolio on best-selling product formats with the strongest margin profile. The Company is in the process of integrating its virtual, physical and third-party clinic platform which is expected to generate additional operating expense savings. The Company reviewed its inventory and fixed assets and identified certain slow-moving assets primarily related to the bulk wholesale sales channel. As a result of the Company’s pivot towards focusing on branded cannabis products, the Company recorded a $19.6 million inventory provision. The Company also recorded a $28.8 million impairment of property, plant & equipment due to changes in market conditions for these assets.
• Adjusted EBITDA Profitability: The Company evaluated all facets of the organization and realigned executive management to focus on achieving profitability. Significant non-recurring one-time costs were incurred in 2021 as the Company developed, built, and launched its Sunday Market House of Brands. Most of these costs are not expected to be recurring. Over the last four quarters, the Company saw significant progress and is trending towards achieving breakeven Adjusted EBITDA profitability in the second half of 2022.
• Repositioning the Balance Sheet. The Company completed two senior secured debt financings in Q4 2021, including a $10 million senior secured term credit facility in August 2021 and a new $19 million credit facility in December 2021. The new credit facility consists of a $12 million term loan and a revolving receivables facility of up to $7 million. The revolving receivables facility remains undrawn, providing the Company with liquidity to fund working capital investments required to continue rapidly scaling its adult-use sales. As reflected in the Company’s announcement on February 1, 2022, the Company is actively engaging with holders of its listed unsecured convertible debentures maturing on June 27, 2022 (TSX: AH.DB) with a view to effecting changes in key terms that are equitable to both the holders and the Company, and provide a sustainable foundation for the Company’s continued growth.
Note that the Company announced on February 8, 2022 that it changed its year-end to March 31. As a result, in this transition year, annual audited financial statements for the 15 months ended March 31, 2022 will be issued prior to June 29, 2022.
Page Break
NET INCOME & ADJUSTED EBITDA
To see all of the numbers look here:
https://aleafiahealth.com/news-releases/aleafia-health-reports-q4-2021-financial-results-with-11-5-million-branded-cannabis-gross-revenue-representing-a-103-increase-from-2020/
Aleafia Health Reports Q4 2021 Financial Results with $11.5 Million Branded Cannabis Gross Revenue, representing a 103% Increase from 2020
https://www.globenewswire.com/news-release/2022/02/15/2384805/0/en/Aleafia-Health-Reports-Q4-2021-Financial-Results-with-11-5-Million-Branded-Cannabis-Gross-Revenue-representing-a-103-Increase-from-2020.html
Notable earnings before Tuesday's open
10:11 AM | Aleafia Health Inc. (ALEAF) | By: Pranav Ghumatkar, SA News Editor
ABG,ACRE,OTCQX:ALEAF,ALLE,ALLT,ARCH,ASC,BKI,BWA,CCRD,CEVA,ECL,OTCPK:ENGIY,ESEA,FIS,OTCQB:FNMA,GILT,OTCPK:GLCNF,HSIC,HUN,IPGP,IQV,KRNT,LDOS,LGIH,MAR,NXRT,PTN,QSR,RPRX,SABR,SAFE,TRP,TRTN,USAC,OTCQX:VYGVF,WCC,YNDX,ZTS
I thought this was going to be a winning cannabis company with a low cost of goods.
Not a winner.
In the videos I saw of Benic, he sure sounded upbeat and knowledgeable. Unfortunately, the stock has been going straight down for a year or so. I sold all my shares five weeks ago. That means ALEAF will probably be rocketing soon!
Aleafia Health Inc (OTCMKTS: ALEAF) Obtains a $19 Million Credit Facility and Extension of Existing Credit Facility
Aleafia Health to Announce Fourth Quarter 2021 Results
TORONTO – February 8, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will announce results from its three and 12-month periods ending December 31, 2021 on February 14, 2022. The Company will also host its earnings conference call on February 15 at 9:30 a.m. EST. The call will be hosted by CEO Tricia Symmes and CFO Matt Sale.
CONFERENCE CALL & WEBCAST
Date: February 15, 2022
Time: 9:30 a.m. ET
USA/Canada Toll-Free Participant Call-in: (866) 679-9046; Passcode: 6187986
International Toll-Free Participant Call-in: (409) 217-8323; Passcode: 6187986
WEBCAST LINK
This conference call will be webcast live over the internet and can be accessed through the link provided. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
Aleafia Health recently changed its fiscal year end from December 31, 2021 to March 31, 2022, and expects to report 2021 fiscal year results by June 29, 2022.
For Investor & Media Relations:
Matt Sale, CFO
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health, a vertically integrated and federally licensed Canadian cannabis company, owns three licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history, and operates a strategically located distribution centre, all in the province of Ontario. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the adult-use and medical markets and is pursuing opportunities in select international jurisdictions. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
It's about time --->>> Aleafia Health Appoints Tricia Symmes as CEO to Replace Geoffrey Benic
TORONTO –February 7, 2022 – The Board of Directors of Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) today announced that CEO Geoffrey Benic will leave the Company, effective February 7, 2022. To succeed Benic, the Board named Tricia Symmes, previously the Company’s Chief Commercial Officer (CCO), as the Company’s new CEO.
https://aleafiahealth.com/news-releases/aleafia-health-appoints-tricia-symmes-as-ceo-to-replace-geoffrey-benic/
“Geoff joined Aleafia in June 2018 at a turning point for the Company,” said Mark J. Sandler, board chair. “He brought to Aleafia Health a strong entrepreneurial background and helped the company develop its diversified indoor, greenhouse and outdoor production capabilities and its class-leading processing facilities. We wish Geoff well as he moves on to pursue other business interests.”
Symmes became Aleafia Health’s CCO in August 2020 and led the move into the branded recreation market, where the company recently entered the top 10 in the key market categories. She has extensive executive C-suite experience in the pharmaceutical, biotech, consumer-packaged, and cannabis industries in both North American and international markets. Before joining Aleafia, Symmes served as Chief Operating Officer and General Manager of multinational companies, including Alcon Canada and Novartis Pharmaceuticals, as well as General Manager at CX Industries, a wholly owned subsidiary of Entourage Health Corp. She is one of the first female CEOs in the Canadian cannabis industry.
“Tricia is exactly the right person to rise to the challenges of today’s market and lead the next phase of the company’s growth. Leveraging her 20 years of experience as a senior executive in salient industries, Aleafia has seen exponential growth in adult-use cannabis net revenue in only 6 months, while the company’s medical business has continued to move from strength-to-strength, including through the unparalleled partnership with Unifor.” said Sandler. “Her elevation to CEO is part of the natural evolution of the company and is based on her demonstrated achievements. We look forward to her continuing to improve the company’s operational efficiency, and to profitably building market share and brand recognition nationally and globally.”
Symmes holds an MBA from Charles Sturt University (Australia), and an Honours BSc in Kinesiology (Western University).
For Investor and Media Relations, please contact:
Matt Sale, Chief Financial Officer
1-833-TSX-ALEF (879-2533)
IR@AleafiaHealth.com
LEARN MORE:www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health, a vertically integrated and federally licensed Canadian cannabis company, owns three licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history, and operates a strategically located distribution centre, all in the province of Ontario. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the adult-use and medical markets and is pursuing opportunities in select international jurisdictions. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Aleafia Health Provides Further Update on its Convertible Debt
Entered into Forbearance Agreement with Holders representing 58% of total Debentures
Negotiating a potential transaction to amend the Convertible Debt terms for all debenture holders
TORONTO – February 1, 2022 – Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is providing a corporate update regarding its outstanding listed unsecured convertible debentures (TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022 (the “Convertible Debt”).
Further to the Company’s announcement on January 4, 2022, Aleafia Health is advancing towards achieving a beneficial outcome for all its stakeholders.
The Company has entered into a Forbearance Agreement (the “Forbearance Agreement”) with Debenture holders representing 58% of the Debentures’ aggregate principal amount outstanding (the “Holders”). An ad hoc Steering Committee comprised of certain Debentureholders, and represented by Bennett Jones, has been established that will help facilitate ongoing negotiations surrounding the Convertible Debt. The Forbearance Agreement’s initial term extends to February 28, 2022, and the agreement automatically renews for 14-day periods thereafter unless notice to the contrary is provided (the “Term”).
Under the Forbearance Agreement, the Holders, among other considerations, forebear in enforcing their rights or remedies against the Company under the Indenture and otherwise at law with respect to the non-payment of interest until the expiry of the Term. The Company, in turn, has agreed to certain customary and standard covenants regarding carrying on business in the ordinary course during the Term.
Under the Forbearance Agreement, the Holders and the Company have agreed to work expeditiously and in good faith to negotiate a potential transaction to amend the terms associated with the Convertible Debt. There can be no assurance that the negotiations will result in a transaction.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
Good news for all companies involved. I prefer to see them cooperate.
Aleafia (in blue below) is using new means to distribute product--->>> FIRE & FLOWER LAUNCHES E-COMMERCE DISPENSARIES FOR CANADIAN LICENSED PRODUCERS' BRANDS
JANUARY, 27, 2022
https://investors.fireandflower.com/news/news-details/2022/Fire--Flower-Launches-E-Commerce-Dispensaries-for-Canadian-Licensed-Producers-Brands/default.aspx
New e-commerce offering from Hifyre and Fire & Flower will equip brands with a direct-to-consumer sales platform enabled by delivery and a 100+ store retail network
TORONTO, Jan. 27, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower'', or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced the expansion of the Company's e-commerce offering with the launch of online branded dispensaries that will enable direct-to-consumer sales using drop shipping for leading licensed producers ("LPs").
The expanded e-commerce capabilities continues the buildout of Fire & Flower's proprietary technology stack that is focused on delivering a seamless digital consumer experience including in-store fulfillment and delivery. The new virtual retail platforms, powered by the Company's proprietary data and analytics platform, Hifyre, allow for cannabis consumers to shop LP-branded online marketplaces for direct-to-consumer sales.
Consumers can shop for their favorite brands' cannabis products and have those orders completed through in-store fulfillment at one of Fire & Flower's 100+ retail locations or via delivery (where permitted) through its recently acquired delivery subsidiary, Pineapple Express Delivery.
Initial brands available for purchase through Fire & Flower's platforms include Auxly, Aleafia, Cronos Group, FIGR and Wagners. The e-commerce marketplaces will also generate digital advertising revenue through the Hifyre Reach platform which connects brands to intending consumers, and provides a path to measure purchasing behavior both in-store and online.
"Retail is continuously evolving and we found that a growing segment of our customer base is looking for a seamless digital solution that allows them to connect and shop directly from their favorite brands. We are uniquely positioned to meet that demand by providing a streamlined retail experience to customers across North America through our scalable, digital solution, powered by our Hifyre technology platform. Through the creation of branded dispensaries we are delivering additional value to LPs by enabling greater customer acquisition through a top-of-funnel virtual platform that can also fulfill those direct orders either in person or via delivery," said Trevor Fencott, Chief Executive Officer of Fire & Flower.
"Not only does the creation of these online platforms support the expansion of our Spark Perks membership program and empower our entire technology platform with increasing sources of consumer buying preferences, it creates an opportunity to generate new digital advertising revenue streams through our Hifyre Reach platform," concluded Fencott.
"We're excited to engage directly with consumers through Fire & Flower's advanced consumer technology," said Andrew MacMillan, SVP Commercial, Auxly. "To successfully compete in today's competitive cannabis market, it is essential to understand purchase habits and preferences. Through our newly branded e-commerce dispensaries, not only can we track consumer activity right through to purchase and conversion, but most importantly, we are also delivering an enhanced experience of our brands. This direct-to-consumer online model will drive new opportunities to more effectively serve our expanding customer base and support our sales growth."
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with over 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre Inc., to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the Hifyre™ digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard Inc. (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of Alberta, Saskatchewan, Manitoba, British Columbia and Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
About Hifyre
The Hifyre Digital Retail and Analytics Platform is a proprietary ecosystem of products that includes the Spark Perks member program, Hifyre ONE retail software platform, Hifyre IQ cannabis data and analytics platform, and Hifyre Reach digital advertising network.
The Hifyre platform also supports Fire & Flower's advanced operations and provides a competitive advantage in providing a tailored digital experience and understanding consumer behaviours in the evolving cannabis market.
To learn more about Hifyre, visit www.hifyre.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements, including market conditions and the business of the Company. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
If they can get a deal with their lenders I think this will squeeze
I am not able to find the details of the benefits deal other than I saw the new benefit brochure that covers annabis for certain conditions and the category is expanding as research comes out.
They also had +31% Q4 over Q3 according to Matt Latimer and Hyfyre data.
I hope the lenders see the potential here. They are on the verge of decent income from the auto workers union UNIFOR paying them premium for their medicines on benefits package. They have been bad at letting folks know about that tho
Almost dead --->>>Aleafia Health Skips Interest Payment As It Looks To Negotiate With Holders Of $37.4 Million In Outstanding Debt
January 4, 2022 8:47 AM
By: Jay Lutz
In a development that is perhaps surprising to absolutely no one, Aleafia Health (TSX: AH) announced this morning it is currently in negotiations with holders of its convertible debt. The debt comes due later this year, on June 27.
Originally issued in June 2019, the debt at issuance raised proceeds of $40.3 million from the company. Of that figure, just $2.9 million has been repaid, with a total outstanding principal amount now pegged at approximately $37.4 million as of September 30.
The firm however did secure a total of $19 million via a term loan and receivables facility just last week. With current cash on hand of just $4.7 million and a further $6.7 million in marketable securities and $8.2 million in trade receivables as of September 30, the firm has little chances of repaying the debt. And with a conversion price of $1.55 per share, there is little hope for the firm to see any further debt settled via equity conversion under the current terms.
In connection with these negotiations being underway, the company has not made an interest payment that was required to be made on December 31. This, however, is not classified as a default until thirty days after the payment is due.
The firm is currently looking to “achieve an outcome that is beneficial to all the Company’s stakeholders.” Notably, the debt is unsecured against the firms assets.
Aleafia Health last traded at $0.135 on the TSX.
It is just part of the cycle. Tax loss selling is over. This is the only LP I own. I have everything else in the US names for the pop on legalization. The Unifor contract keeps me in this one it will fly when all those achey auto workers start realizing they can get weed through their benefits.
That is unfortunate. I had high hopes for this with the union deal starting to come to fruition. Hopefully if is jyst a hiccup. Thank you very much for sharing. It sucks not being able to advertise.
Is 5¢ next?--->>>Aleafia Health Announces Closing of a New $19 Million Credit Facility and Extension of Existing Credit Facility
• Credit Facility provides the Company with liquidity to fund operations and organic growth initiatives --->>> What a shame. This isn't money for growth. It's money to keep the lights on. - FUNMAN
• Two-year term provides additional financial flexibility
TORONTO – December 29, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the closing of a credit facility of up to $19 million (the “Credit Facility”).
“This financing improves our liquidity and capital structure as the Company’s senior secured debt obligations will now mature in December 2023 rather than in August 2022,” said Aleafia Health CEO Geoffrey Benic. “The transaction allows us to continue the growth of our core adult-use and medical cannabis sales channels, as we again expect to realize sequential growth in both channels over the previous quarter.”
The Credit Facility is financed by the Garrington Group of Companies, a Toronto-based private lender providing working capital financing to the underserved, small to mid-sized middle market sector across North America, providing credit facilities that generally range from $1 million to over $30 million. It consists of a revolving receivables facility of up to $7 million and a term loan of $12 million. The maturity date is December 2023. The term loan was fully drawn by the Company upon closing. The revolving receivables facility is expected to be drawn in January 2022 and further thereafter as receivables grow with the Company’s revenue. The interest rate is in-line with the Company’s existing credit facility and is payable monthly. The Credit Facility is secured primarily by way of first lien mortgages on the Company’s Paris, Ontario and Grimsby, Ontario production facilities, and includes customary financial and restrictive covenants. The net proceeds from the Credit Facility will be used to fund working capital, to repay $5 million in principal on the existing senior secured credit facility, announced on August 23, 2021 (the “August Credit Facility”), along with accrued interest and fees, and for general corporate purposes.
The term of the August Credit Facility has been extended from August 2022 to December 2023. In connection with that facility, a first lien mortgage will be granted on the Company’s Port Perry, Ontario outdoor cultivation property.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The Company has developed an international footprint, with subsidiaries or investments in German and Australian medical cannabis companies and has products available in both markets.
The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners who have seen over 75,000 patients to date.
Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the medical and adult-use markets, and in select international jurisdictions.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com.
Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
It is worth the wait.
How many months/years/decades has it been since this last occurred?? :)
Auto workers can not get those on their benefit plan. Aleafia has an edge. Kinslips are excellent. I have family members who use them and get great results
Competition to Kin-Slips--->>> Launch of Tilray’s Fast-Acting Oral Strips Highlights Commitment to Medical Cannabis Innovation and Patient Care
December 2, 2021 at 7:30 AM EST
https://ir.tilray.com/news-releases/news-release-details/launch-tilrays-fast-acting-oral-strips-highlights-commitment
Aphria Branded Medical Cannabis Oral Strips Powered by QuickStrip™ Innovation Now Available to Patients Throughout Canada
NEW YORK and LEAMINGTON, Ontario, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that its medical subsidiary, Aphria, has launched medical cannabis oral strips in THC and CBD-rich varieties. Powered by QuickStrip’s™ proprietary technology, each Aphria medical strip contains a thin, edible film that contains rapidly dissolving, micronized cannabinoids that absorb directly into the bloodstream, providing patients with a fast-acting, convenient, and precise dosing experience for relief from a range of conditions.
Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, said, “Tilray’s medical brands, Aphria, Symbios, and Tilray, are relentlessly committed to investing in patient wellness through a portfolio of new innovative product offerings, GMP-certified cultivation, and the earned trust of the medical community. The launch of the Aphria-branded medical strips is a compelling proof point in this regard, and, given the growing expansion of medical cannabis across the globe, we believe we are exceptionally well-positioned in this high-growth, high-margin market moving forward. We look forward to extending our leadership in medical cannabis and to delivering value for patients and shareholders alike.”
Blair MacNeil, President at Tilray Canada, added, “At Aphria Medical, our goal is to be the trusted partner for patients by providing them with high-quality, precise, and efficacious medical cannabis treatment. Delivering on this mission means meeting patients ‘where they are,’ including those who are unable or reluctant to swallow medication or do not prefer the taste of cannabis oil. To address this need, Aphria has pioneered a superior, non-combustible, discreet, and easy-to-use method of consumption that utilizes micronized cannabinoids for rapid absorption and relief from a range of conditions.”
The strips, which are now available throughout Canada, are available in three different cannabis ratios: THC 10, CBD 20:1, and THC:CBD 10:10 (coming soon). Each pack of Aphria oral strips comes with 30 individually wrapped strips for precise, single-dose delivery.
About Aphria Medical
Aphria Medical started in 2014 in Leamington, Ontario, as one of the first companies to provide access to legal medical cannabis. Since then, the Aphria brand has grown to be one of the top medical cannabis providers globally, with operations in Canada and international markets. Aphria remains committed to supplying its growing patient base with safe, affordable, consistent, and effective medical cannabis products.
For more information, visit: www.aphria.ca
About Tilray
Tilray, Inc. (Nasdaq: TLRY; TSX: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information about Tilray medical cannabis products, visit: www.Tilray.ca
For more information about Tilray, visit www.Tilray.com
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world's leading cannabis-focused consumer branded company with our target of $4 billion of revenue by 2024; the Company’s position and plans to be the #1 Canadian LP in total sales on a consolidated basis; management’s projected growth in market share and revenue in the EU cannabis market and its Sweetwater and Manitoba Harvest businesses; and expectations regarding the Company’s achievement of synergy targets. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
For media inquiries, please contact:
Jaydon Case
news@tilray.com
For investor inquiries please contact:
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com
JMO—An R/S is in the future here
ALEAF—My biggest bag of 2021–GLTA!
If the US was not so close to go time I would add here. So many opportunities so little cash :)
We are officially in the ….. zone.
I think this might of made a possible double bottom previous low back showing .199 back in March 2020.
The canadian landscape has been extremely challenging and these guys have been creative and nimble in their navigation. They have done what they said they were going to do and I really think the union deal is going to be very helpful. The fact they have so much product on the government sites is a big plus. There is no legal company I know of in canada with as much going for it as these guys do. They are lining up their supply with the demand. I am not happy with the loss but if it clears the balance sheet for growth it is just another growing pain. I would rather own this than canopy lol!
Thank heavens for now that's all it is.
How are they not going to do an R/S?
I am left to hope for a big Q4 once the harvest is processed.
Is 331,007,629 O/S a lot for a company like this?
Aleafia Health Reports Q3 2021 Financial Results with 123% Increase in Cannabis Net Revenue
https://financialpost.com/globe-newswire/aleafia-health-reports-q3-2021-financial-results-with-123-increase-in-cannabis-net-revenue
Interesting. Just listened. Thanks.
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3373
|
Created
|
12/08/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |